Clinical trials: Progressive Supranuclear Palsy
Parkinson Disease, Progressive Supranuclear Palsy
Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes
Parkinson's disease (PD) is the most common degenerative Parkinson's syndrome and is linked, among other things, to the excessive accumulation of an abnormally aggregating protein, alpha-synuclein.
- Trial name
- SODIPARK (NCT06155942)
- Testing
- 7 Tesla MRI
- Where
- 6 sites in France
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Progressive Supranuclear Palsy (PSP), Healthy Participants
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
This clinical study is being conducted to learn more about two new imaging drugs, called [18F]ABBV-964i and [18F]ABBV-965i, which are designed to help doctors see changes in the brain related to a condition called Progressive…
- Trial name
- NCT07348276
- Testing
- [18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Invicro
Parkinson's Disease, Multiple System Atrophy
Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Syndromes
Parkinsonian syndrome is clinically characterized by the presence of resting tremor, rigidity, bradykinesia and postural instability.
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Vascular Parkinsonism
- Trial name
- PARKIMAGE (NCT02445469)
- Testing
- MRI exam of the brain
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Progressive Supranuclear Palsy, Brain Diseases
Personalized Parkinson Project PSP Cohort
There is an urgent need for the development of digital progression biomarkers, which are sensitive to detect small, but potentially clinically relevant changes in the disease course.
- Conditions
- Progressive Supranuclear Palsy, Brain Diseases, Neurodegenerative Diseases, Movement Disorders
- Trial name
- PPP-PSP (NCT05501431)
- Testing
- Verily Study Watch
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Progressive Supranuclear Palsy
Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy
Study hypothesis: A 6-week p.o treatment with 5 mg/Kg Coenzyme Q10 is safe and tolerable,increases the brain's metabolism and ameliorates clinical symptoms in patients with PSP.
- Trial name
- NCT00328874
- Testing
- Coenzyme Q10
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- German Parkinson Study Group (GPS)
Alzheimer's Disease (AD), Parkinson's Disease (PD)
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
The goal of this study is to assess [18F]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease…
- Conditions
- Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT02103894
- Testing
- [18F]T807 ([18F]MNI-777)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Frontotemporal Dementia, Progressive Supranuclear Palsy
Study of the Neural Basis of Analogical Reasoning
Frontal patients are impaired in categorisation and analogical reasoning tasks, and different functional imaging studies from our group have shown the involvement of the prefrontal cortex in categorisation and analogy tasks.
- Conditions
- Frontotemporal Dementia, Progressive Supranuclear Palsy, Healthy Subjects
- Trial name
- ANALOG (NCT02236832)
- Testing
- transcranial magnetic stimulation, MRI imaging, EEG recording
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American…
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT04363684
- Where
- 26 sites in United States, Canada
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Alzheimer Disease, Progressive Supranuclear Palsy
Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls
This is an experimental medicine study to evaluate the kinetics of cerebrospinal fluid (CSF) biomarkers in subjects with Alzheimer's disease (AD) or progressive supranuclear palsy (PSP) compared to healthy controls using a heavy…
- Trial name
- NCT01348061
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- KineMed
Progressive Supranuclear Palsy, Dementia With Lewy Bodies
In-Home Care for Patients With PSP and Related Disorders
Progressive Supranuclear Palsy and related disorders (PRD) are debilitating, costly, and understudied conditions. Improving access to comprehensive, specialized, in-home patient care offers the potential to minimize the downward…
- Conditions
- Progressive Supranuclear Palsy, Dementia With Lewy Bodies, Multiple System Atrophy, Corticobasal Syndrome
- Trial name
- NCT03552484
- Testing
- Home Visit Program, Usual Care/Online Survey
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Progressive Supranuclear Palsy
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT02605785
- Testing
- F-18 AV 1451
- Where
- United States
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Progressive Supranuclear Palsy
Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy
Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease from the parkinsonian syndrome group. PSP is characterised by the association of a non-doparesponsive parkinsonian syndrome with axial signs.
- Trial name
- Qual-PSP (NCT03638505)
- Testing
- PSP-QoL
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP)
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
The overall goal of this imaging trial is to characterize [18F]MNI-815, a PET radioligand for imaging Tau.
- Conditions
- Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
- Trial name
- NCT02531360
- Testing
- [18F]MNI-815 (MNI-815)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Corticobasal Syndrome(CBS), Primary Progressive Aphasia(PPA)
Neuroinflammation in FTLD
The goal of this observational study is to investigate the role of neuroinflammation in frontotemporal lobar degeneration (FTLD). The main aims of this study are: 1.
- Conditions
- Corticobasal Syndrome(CBS), Primary Progressive Aphasia(PPA), Progressive Supranuclear Palsy(PSP), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT06870838
- Testing
- 7T MRI scan, CSF, Blood withdrawal
- Where
- 2 sites in Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Parkinson's Disease, Parkinson-Dementia Syndrome
Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease
The PET tracer Fluoro-ethyl-methyl-amino-naphthyl-ethylidene-malononitrile ([F18]-FDDNP) has a specific affinity for lesions containing tau protein and beta-amyloid The study consists of two phases In a first transversal phase, 8…
- Trial name
- NCT02243982
- Testing
- [F18]-FDDNP
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Parkinson's Disease, Parkinsonism
VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and Parkinsonism
VISMEMO-PD is an observational pilot study aimed at investigating visuospatial memory in reaching space and topographical memory in navigational space in patients with Parkinson's disease and Parkinsonism.
- Conditions
- Parkinson's Disease, Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- VISMEMO-PD (NCT07827963)
- Testing
- Multimodal visuospatial and topographical memory assessment
- Where
- 3 sites in Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele Roma
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Neurodegenerative Disease, Behavioral Variant Frontotemporal Dementia (bvFTD)
Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases
Neurodegenerative diseases, including frontotemporal lobar degeneration (FTLD) spectrum syndromes, are characterized by the accumulation of insoluble protein aggregates in the central nervous system.
- Conditions
- Neurodegenerative Disease, Behavioral Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia(PPA), Progressive Supranuclear Palsy(PSP)
- Trial name
- NCT07567664
- Testing
- 3 Tesla MRI without contrast medium, Blood sample for genetic analysis, Cerebrospinal fluid sampling (CSF)
- Where
- Italy
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Parkinson Disease, Multiple System Atrophy
Diagnostic and Prognostic Biomarkers in Parkinson Disease
The overall goal of PROBE is to evaluate the feasibility and potential utility of three markers (alpha-synuclein, transcriptomic profiles and olfactory function) to determine the risk or prognosis of PD.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- PROBE (NCT00653783)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Parkinson Study Group
Atypical Parkinsonism
Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans
The primary aim of this study is to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana.
- Trial name
- CAP (NCT03368300)
- Testing
- Clinical and biological exam
- Where
- 2 sites in French Guiana, Martinique
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe